A Phase 3 interventional study of RSVpreF Vaccine and Placebo in Respiratory Syncytial Virus, sponsored by Pfizer. Completed at 16 sites in South Korea. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Respiratory Tract Infections by Pfizer — 2 open to participants now, 3 under way, 2 of them phase 3. Respiratory Tract Infections · Pfizer.
Among the 23 studies in Respiratory Tract Infections by Pfizer, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 3, and was the 19th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
Browse Respiratory Tract Infections studies →2 of the 23 studies in Respiratory Tract Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
By country, each count listing its studies:
Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 378 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 309 across the 18 interventional studies, 421 across the 5 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Respiratory Tract Infections by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Respiratory Tract Infections by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to quantify the immune response in older Korean adults after a RSVpreF vaccination. It will also learn about the safety and tolerability of RSVpreF vaccination. The main questions it aims to answer are:
What local reactions and systemic events do participants have after a RSVpreF vaccination? What medical problems do participants have after a RSVpreF vaccination? Researchers will compare RSVpreF to a placebo (a look-alike substance that contains no RSVpreF) to see if RSVpreF is safe and well tolerated. It will also examine the change in antibody levels (immune responses) before and after vaccination.
Participants will:
Receive the RSVpreF vaccination or a placebo injection once at Visit 1. Visit the clinic a month later for a checkup and tests. Receive a phone call 1 week after vaccination, and 2 months after vaccination, for health checks.
Keep a diary of their symptoms for 7 days after vaccination.
This is a Phase 3, randomized, double-blinded, placebo-controlled, multicenter trial to describe the safety, tolerability, and immunogenicity of bivalent RSVpreF in adults 60 years of age and older in Korea.
The study duration is approximately 2 months. 4 study visits are required and are comprised of 2 scheduled clinic visits and 2 scheduled telephone calls.
Approximately 360 study-eligible participants will be randomized to receive either the 120-µg dose of RSVpreF or placebo in a 2:1 ratio.
After screening and confirmation of eligibility, a prevaccination blood sample will be collected for immunogenicity assessments and a single dose of study intervention (RSVpreF or placebo) will be administered.
Participants will report daily reactogenicity data using an electronic device for 7-days or until resolution.
Participants will return approximately 1 month later for a follow-up blood draw for immunogenicity assessments and collection of safety information.
A telephone follow-up visit will be conducted approximately 1 week after vaccination to review reactogenicity and approximately 2 months after vaccination to collect safety information.
For all participants, adverse events (AEs) will be collected from informed consent through 1 month following study intervention administration. Serious adverse events (SAEs) newly diagnosed chronic medical conditions (NDCMCs), and adverse events of special interest (AESIs) will be collected from informed consent throughout study participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants 60 years of age or older at Visit 1
Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.
Exclusion Criteria:
Individuals who receive chronic systemic treatment with immunosuppressive therapy (other than systemic meeting the criteria noted below), including cytotoxic agents, immunosuppressive monoclonal antibodies, or radiotherapy, eg, for cancer or an disease, from 60 days before study intervention administration or planned receipt throughout the study.
Receipt of systemic corticosteroids (≥20 mg/day of prednisone or equivalent) for
≥14 days from 28 days before study intervention.
Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: RSVpreF Vaccine
Other: Placebo
RSV Vaccine 120 mcg
Placebo
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Local reactions included redness, swelling and pain at injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm, moderate: \> 5.0 cm to 10.0 cm, severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity, severe: prevented daily activity. Any local reaction: any redness, any swelling, or pain at the injection site of at least mild severity. Exact 2-sided 95% confidence interval (CI) was based on the Clopper and Pearson method.
Time frame: From Day 1 to Day 7 after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C, and Grade 4: \>40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From Day 1 to Day 7 after vaccination
Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From vaccination on Day 1 up to 1 month after vaccination
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study
An SAE was defined as an AE that, at any dose met one of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic; other significant medical events as judged by investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From vaccination on Day 1 up to 2 months after vaccination
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study
A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From vaccination on Day 1 up to 2 months after vaccination
Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B Before Vaccination
GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ for analysis.
Time frame: Before Vaccination
Geometric Mean Titer (GMT) of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination
GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ for analysis.
Time frame: 1 month after vaccination
Geometric Mean Fold Rise (GMFR) of Neutralizing Titers (NTs) for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination
Fold rises was defined as ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
Time frame: From before vaccination to 1 month after vaccination
Seroresponse Rates of Neutralizing Titers (NTs) for RSV A and RSV B at 1 Month After Vaccination
Seroresponse rate was defined as the percentage of participants with a postvaccination NT \>=4 times the LLOQ if the baseline titer (before vaccination) was below the LLOQ; or a \>=4-fold rise from baseline if the baseline titer was\>=LLOQ. 95% CI was based on Clopper-Pearson method.
Time frame: 1 month after vaccination
This study was conducted at 16 sites in the Republic of Korea.
| Milestone | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Started | 252 | 126 |
| Vaccinated | 251 | 126 |
| Completed | 250 | 126 |
| Not completed | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Randomized, not vaccinated | 1 | 0 |
Local reactions included redness, swelling and pain at injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm, moderate: \> 5.0 cm to 10.0 cm, severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity, severe: prevented daily activity. Any local reaction: any redness, any swelling, or pain at the injection site of at least mild severity. Exact 2-sided 95% confidence interval (CI) was based on the Clopper and Pearson method.
| Percentage of participants | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Pain at injection site: any | 12.4 (8.5 to 17.1) | 3.2 (0.9 to 7.9) |
| Pain at injection site: mild | 11.6 (7.9 to 16.2) | 2.4 (0.5 to 6.8) |
| Pain at injection site: moderate | 0.8 (0.1 to 2.8) | 0.8 (0.0 to 4.3) |
| Pain at injection site: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Redness: any | 2.8 (1.1 to 5.7) | 0.8 (0.0 to 4.3) |
| Redness: mild | 1.6 (0.4 to 4.0) | 0.8 (0.0 to 4.3) |
| Redness: moderate | 0.8 (0.1 to 2.8) | 0 (0.0 to 2.9) |
| Redness: severe | 0.4 (0.0 to 2.2) | 0 (0.0 to 2.9) |
| Swelling: any | 1.6 (0.4 to 4.0) | 0.8 (0.0 to 4.3) |
| Swelling: mild | 1.2 (0.2 to 3.5) | 0.8 (0.0 to 4.3) |
| Swelling: moderate | 0.4 (0.0 to 2.2) | 0 (0.0 to 2.9) |
| Swelling: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Any local reaction: any | 14.7 (10.6 to 19.7) | 3.2 (0.9 to 7.9) |
| Any local reaction: mild | 12.4 (8.5 to 17.1) | 2.4 (0.5 to 6.8) |
| Any local reaction: moderate | 2.0 (0.6 to 4.6) | 0.8 (0.0 to 4.3) |
| Any local reaction: severe | 0.4 (0.0 to 2.2) | 0 (0.0 to 2.9) |
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C, severe: \>38.9 to 40.0 deg C, and Grade 4: \>40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Fever: >=38.0°C | 0.4 (0.0 to 2.2) | 1.6 (0.2 to 5.6) |
| Fever: >=38.0°C to 38.4°C | 0 (0.0 to 1.5) | 1.6 (0.2 to 5.6) |
| Fever: >38.4°C to 38.9°C | 0.4 (0.0 to 2.2) | 0 (0.0 to 2.9) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Fever: >40.0°C | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Fatigue: any | 23.1 (18.0 to 28.8) | 26.2 (18.8 to 34.8) |
| Fatigue: mild | 17.9 (13.4 to 23.2) | 15.9 (10.0 to 23.4) |
| Fatigue: moderate | 5.2 (2.8 to 8.7) | 10.3 (5.6 to 17.0) |
| Fatigue: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Headache: any | 12.7 (8.9 to 17.5) | 11.1 (6.2 to 17.9) |
| Headache: mild | 11.6 (7.9 to 16.2) | 8.7 (4.4 to 15.1) |
| Headache: moderate | 1.2 (0.2 to 3.5) | 2.4 (0.5 to 6.8) |
| Headache: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Muscle pain: any | 15.5 (11.3 to 20.6) | 9.5 (5.0 to 16.0) |
| Muscle pain: mild | 12.0 (8.2 to 16.6) | 5.6 (2.3 to 11.1) |
| Muscle pain: moderate | 3.6 (1.7 to 6.7) | 4.0 (1.3 to 9.0) |
| Muscle pain: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Joint pain: any | 9.2 (5.9 to 13.4) | 7.9 (3.9 to 14.1) |
| Joint pain: mild | 6.0 (3.4 to 9.7) | 4.0 (1.3 to 9.0) |
| Joint pain: moderate | 3.2 (1.4 to 6.2) | 4.0 (1.3 to 9.0) |
| Joint pain: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Nausea: any | 3.6 (1.7 to 6.7) | 6.3 (2.8 to 12.1) |
| Nausea: mild | 3.6 (1.7 to 6.7) | 4.0 (1.3 to 9.0) |
| Nausea: moderate | 0 (0.0 to 15) | 2.4 (0.5 to 6.8) |
| Nausea: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Vomiting: any | 0 (0.0 to 1.5) | 0.8 (0.0 to 4.3) |
| Vomiting: mild | 0 (0.0 to 1.5) | 0.8 (0.0 to 4.3) |
| Vomiting: moderate | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Vomiting: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Diarrhea: any | 4.8 (2.5 to 8.2) | 4.0 (1.3 to 9.0) |
| Diarrhea: mild | 4.8 (2.5 to 8.2) | 4.0 (1.3 to 9.0) |
| Diarrhea: moderate | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
| Diarrhea: severe | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination | 3.6 (1.7 to 6.7) | 0.8 (0.0 to 4.3) |
An SAE was defined as an AE that, at any dose met one of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic; other significant medical events as judged by investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination Throughout the Study | 0.8 (0.1 to 2.8) | 0.8 (0.0 to 4.3) |
A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study | 1.2 (0.2 to 3.5) | 0 (0.0 to 2.9) |
GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ for analysis.
| Titer | RSVpreF 120 mcg | Placebo |
|---|---|---|
| RSV A | 1472 (1326 to 1636) | 1617 (1402 to 1866) |
| RSV B | 1957 (1766 to 2168) | 1865 (1601 to 2174) |
GMTs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ for analysis.
| Titer | RSVpreF 120 mcg | Placebo |
|---|---|---|
| RSV A | 14240 (12977 to 15625) | 1397 (1199 to 1628) |
| RSV B | 16277 (14623 to 18117) | 1813 (1554 to 2115) |
Fold rises was defined as ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
| Fold rise | RSVpreF 120 mcg | Placebo |
|---|---|---|
| RSV A | 9.5 (8.51 to 10.67) | 0.9 (0.78 to 0.94) |
| RSV B | 8.3 (7.37 to 9.39) | 1.0 (0.89 to 1.06) |
Seroresponse rate was defined as the percentage of participants with a postvaccination NT \>=4 times the LLOQ if the baseline titer (before vaccination) was below the LLOQ; or a \>=4-fold rise from baseline if the baseline titer was\>=LLOQ. 95% CI was based on Clopper-Pearson method.
| Percentage of participants | RSVpreF 120 mcg | Placebo |
|---|---|---|
| RSV A | 81.0 (75.6 to 85.7) | 0.8 (0.0 to 4.4) |
| RSV B | 75.9 (70.1 to 81.1) | 0.8 (0.0 to 4.3) |
Collected over All-cause mortality and SAEs: From vaccination on Day 1 up to 2 months after vaccination. Other AEs (non-systematic assessment): From vaccination on Day 1 up to 1 month after vaccination; Local reactions and systemic events (systematic assessment): From Day 1 to Day 7 after vaccination. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSVpreF 120 mcg | 0/251 (0%) | 2/251 (0.8%) | 100/251 (39.8%) |
| Placebo | 0/126 (0%) | 1/126 (0.8%) | 43/126 (34.1%) |
| Event | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Retinal detachmentEye disorders | 0/251 | 1/126 |
| EnteritisGastrointestinal disorders | 1/251 | 0/126 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/251 | 0/126 |
| Event | RSVpreF 120 mcg | Placebo |
|---|---|---|
| Fatigue (FATIGUE)General disorders | 58/251 | 33/126 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 39/251 | 12/126 |
| Headache (HEADACHE)Nervous system disorders | 32/251 | 14/126 |
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 31/251 | 4/126 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 23/251 | 10/126 |
| Nausea (NAUSEA)Gastrointestinal disorders | 9/251 | 8/126 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 12/251 | 5/126 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 7/251 | 1/126 |
| Swelling (SWELLING)General disorders | 4/251 | 1/126 |
| Pyrexia (FEVER)General disorders | 1/251 | 2/126 |
Safety population included all screened participants who received the study intervention in the study.
| Age, Continuous(Years) | RSVpreF 120 mcg | Placebo | Total |
|---|---|---|---|
| Mean | 67.3 ± 5.18 | 67.3 ± 5.19 | 67.3 ± 5.17 |
| Sex: Female, Male(Participants) | RSVpreF 120 mcg | Placebo | Total |
|---|---|---|---|
| Female | 168 | 76 | 244 |
| Male | 83 | 50 | 133 |
| Race/Ethnicity, Customized(Participants) | RSVpreF 120 mcg | Placebo | Total |
|---|---|---|---|
| Race — Asian | 251 | 126 | 377 |
| Race/Ethnicity, Customized(Participants) | RSVpreF 120 mcg | Placebo | Total |
|---|---|---|---|
| Ethnicity — Non-Hispanic/non-Latino | 251 | 126 | 377 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2024 to primary completion in Feb 2025, 3 months.
Results were first posted in Feb 2026, 1 year after primary completion.
Of 41 phase 3 interventional studies under Respiratory Tract Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 73. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrysvo
Respiratory Tract Infections →